KFDA announces voluntary withdrawal of Zelmac

Published: 2007-04-06 06:56:00

Updated: 2007-04-06 06:56:00

The Korea Food and Drug Administration (KFDA) announced on April 2 that Novartis Korea has halted sales of Zelmac (tegaserod), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, including angina and stroke, in those taking the dr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK